Pexastimogene Devacirepvec

Summary

Pexastimogene Devacirepvec (CHEMBL3039547) is a phase-3 clinical-stage gene; indicated across 10 conditions including hepatocellular carcinoma and colorectal adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 10 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3039547
Name	Pexastimogene Devacirepvec
Type	Gene
Max phase	3

Also known as: JX-594, Pexastimogen devacirepvec, Pexastimogene devacirepvec, PEXASTIMOGENE DEVACIREPVEC

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
colorectal adenocarcinoma	2	MONDO:0005008	EFO:0000365
colorectal carcinoma	2	MONDO:0024331	EFO:1001951
ovarian cancer	2	MONDO:0008170	MONDO:0008170
renal cell carcinoma	1	MONDO:0005086	EFO:0000681
melanoma	1	MONDO:0005105	EFO:0000756
metastatic neoplasm	1	MONDO:0024883	EFO:0009709
neoplasm	1	MONDO:0005070	EFO:0000616
metastatic melanoma	1	MONDO:0005191	EFO:0002617

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1/PHASE2	3
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00429312	PHASE1/PHASE2	COMPLETED	A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
NCT01394939	PHASE1/PHASE2	COMPLETED	Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
NCT02017678	PHASE2	WITHDRAWN	Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin
NCT02630368	PHASE1/PHASE2	UNKNOWN	A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)
NCT01469611	PHASE1	COMPLETED	A Trial of JX-594 in Refractory Colorectal Carcinoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).